According to Expert Market Research, the vasculitis drug pipeline is evolving rapidly as pharmaceutical and biotechnology companies focus on meeting the growing need for targeted treatments. Vasculitis, an umbrella term for a group of rare autoimmune diseases that cause inflammation of blood vessels, has an estimated annual incidence of 20–40 cases per million individuals in Europe and...